Clinical trials: Healthy Volunteers Overweight
Weight Gain, Healthy Subjects
Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition
Background: Rates of obesity have increased dramatically in recent decades, and researchers are investigating how changes in diets and physical activity have contributed to this increase.
- Conditions
- Weight Gain, Healthy Subjects, Obesity, Women
- Trial name
- NCT01251887
- Testing
- Linoleic Acid, Docosahexaenoic Acid, Eicosapentaenoic Acid
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Obesity, Healthy Volunteers
Brain Dopamine Function in Human Obesity
Background: Dopamine is a natural chemical in the brain that may influence eating behavior and physical activity. Researchers want to measure the brain s dopamine activity and understand how it differs in people with obesity.
- Conditions
- Obesity, Healthy Volunteers, Overweight
- Trial name
- NCT03648892
- Testing
- [c11] raclopride, [18F]fallypride
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Volunteer
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants.
- Trial name
- NCT04839393
- Testing
- PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Reduced Carbohydrate Versus Fat in Obese Subjects
Popular weight loss strategies often involve reducing an individual's consumption of carbohydrates or fat. However, no controlled study has been carried out to evaluate the effects of reducing carbohydrate versus fat consumption…
- Trial name
- NCT00846040
- Testing
- Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy
Pharmacokinetics of Voriconazole in Obese Subjects
Obese subjects may require a higher fixed oral maintenance dosing regimen of voriconazole compared to normal weight subjects to achieve comparable plasma exposures. The current study is designed to address this issue.
- Trial name
- NCT01030653
- Testing
- Voriconazole low dose, Voriconazole high dose
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Manjunath Prakash Pai
Healthy
A Study of LY3463251 in Healthy Participants
The purpose of this study is to evaluate the safety and tolerability (side effects) of single (Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously (under the skin) into the abdomen.
- Trial name
- NCT03764774
- Testing
- LY3463251
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dyslipidemias
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
- Trial name
- NCT02714569
- Testing
- LY3202328, Atorvastatin, Simvastatin
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight
A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
This study in healthy men and women looks at the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (s.c., under the skin).
- Conditions
- Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
- Trial name
- NCT04143945
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy, Obese
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese…
- Conditions
- Healthy, Obese, Overweight, Obesity
- Trial name
- NCT06440980
- Testing
- Orforglipron
- Where
- 7 sites in United States
- Volunteers
- 533 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study
The primary goal of this study is to evaluate the feasibility of detecting Brown Adipose Tissue (BAT) in healthy subjects by using hyperpolarized xenon gas MRI.
- Trial name
- NCT02220426
- Testing
- Xenon
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Overweight and Obesity
Predictors of Lorcaserin-Induced Weight Loss
This two-phase study aims to explore ways to predict who will respond well to the weight loss drug lorcaserin and to understand the mechanisms that develop which limit drug efficacy.
- Trial name
- NCT03353220
- Testing
- Belviq
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Columbia University
Healthy Volunteers, Diabetes Mellitus, Type 2
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin).
- Conditions
- Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT04189848
- Testing
- Semaglutide, Dulaglutide
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Pre-diabetes
Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)
The investigators know that metformin works at the level of the cells in the body by acting on a protein called Cyclic amine monophosphate- Response Binding Elements (CREB) binding protein or Constitutive Reverter of eIF2α…
- Conditions
- Diabetes, Pre-diabetes, Obesity
- Trial name
- NCT01876992
- Testing
- Metformin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Obesity
A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects
When humans eat, the bowels naturally secrete chemicals into the bloodstream which make people feel full and which stop eating. One of these chemicals is known as "Pancreatic Polypeptide" (PP).
- Trial name
- NCT01052493
- Testing
- PP 1420
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Obesity, Overweight
Mobile Attention Retraining in Overweight Female Adolescents
Background: People are constantly exposed to unhealthy foods. Some studies of adults show that training attention away from unhealthy foods might reduce overeating.
- Conditions
- Obesity, Overweight, Binge Eating, Healthy Volunteers
- Trial name
- NCT02977403
- Testing
- Attention Bias Retraining
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight
A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
This study in healthy men and women compares the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (sc, under the skin).
- Conditions
- Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
- Trial name
- NCT04007107
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- Netherlands
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
End Stage Cardiac Failure, Pulmonary Failure
Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol
Levels of tocotrienol in human tissues following supplementation is not currently known. The objective of this present study is to determine the levels of this form of vitamin E in the human tissues such as skin, heart, lung…
- Conditions
- End Stage Cardiac Failure, Pulmonary Failure, End Stage Liver Disease, Morbid Obesity
- Trial name
- NCT00678834
- Testing
- To surgery patients, Tocopherol capsules., Tocotrienol to healthy subjects., To surgery patients, Tocotrienol capsules.
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chandan K Sen
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos